Other substances

Covax-19

COVID-19 candidate vaccine

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
2
 Clinical trials

General information

Covax-19 is a candidate vaccine being developed by Vaxine Pty Ltd and Medytox. It is a recombinant spike protein with AdvaxTM adjuvant type of candidate vaccine. It is based on the protein subunit platform. Currently, this COVID-19 candidate vaccine is in Phase I clinical evaluation. 

 

Supporting references

Link Tested on Impact factor Notes Publication date
Draft landscape of COVID-19 candidate vaccines
healthy adults Jul/28/2020

AI-suggested references

Link Publication date
Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection.
Aug/03/2021
Covax-19/Spikogen vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters
Aug/25/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05148871 Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine Recruiting Phase 2|Phase 3 Mar/01/2022 Mar/01/2023
  • Alternative id - C19-P2/3B
  • Interventions - Biological: Spikogen/Covax-19
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ARASMI, Adelaide, South Australia, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Spike antibody immunogenicity|Spike antibody seroconversion|SARS-CoV-2 protection|Spike antibody durability|Spike antibody seropositive persistence
NCT04428073 Therapeutic Vaccine Trial of COVID-19 for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Not yet recruiting Phase 1 Jul/01/2020 Dec/01/2021
  • Alternative id - GC004
  • Interventions - Biological: Covax-19™
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 32
  • Age - 18 Years to 60 Years   (Adult)
  • Outcome measures - To evaluate the safety of a therapeutic Covid-19 vaccine in participants by measuring the severity of local and systemic adverse events and laboratory abnormalities.|To evaluate the immunogenicity of a therapeutic Covid-19 vaccine in participants by measuring CD8+ T cells immune response|Virologic response after vaccination|Clinical outcome and progression after vaccinations
Export (.csv)